title: Incidence of development of obesity after heart transplantation according to the calcineurin inhibitor.
abstract: BACKGROUND
  Development of obesity after heart transplantation (HT) is a common complication, largely attributed to immunosuppressive therapy. The objective of this study is to compare the incidence of development of obesity after HT, according to the calcineurin inhibitor (CNI) used (cyclosporine [CsA] vs tacrolimus [Tac]).
  
  
  METHODS
  We studied 101 consecutive HT patients from November 2006 to December 2010. A diagnosis of overweight-obesity was made by a body mass index of ≥25 kg/m(2), which was assessed before HT and at 1 year after HT. Patients were randomly assigned to the administration of CsA or Tac by a simple randomization method using a computer program (56% received CsA and 44% Tac).
  
  
  RESULTS
  Of the 101 patients, 77% were men, and ischemic heart disease was the most common indication for HT. At baseline, there were no differences in weight between groups treated with CsA or Tac. The mean weight for each group was 71.5 ± 12 and 75 ± 14 kg, respectively (P = .2). The weight increase was greater among CsA patients: after HT, the weight gain was 6.9 ± 11 kg in the CsA group, whereas a minimal weight loss of 0.03 ± 14 kg (P = .008) was experienced in the group treated with Tac. The multivariate analysis showed that only CsA treatment was an independent predictor of development of obesity 1 year after HT (odds ratio, 3.84; 95% CI, 1.04-14.21; P = .01).
  
  
  CONCLUSIONS
  Weight gain after HT may be related to the CNI used and CsA seems to be the CNI that produces the greatest increase.
authors: Department of Cardiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Electronic address: cune10@hotmail.com.
authors: R
authors: R
authors: López-Vilella
authors: Department of Cardiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors: I J
authors: IJ
authors: Sánchez-Lázaro
authors: Department of Cardiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors: L
authors: L
authors: Martínez-Dolz
authors: Department of Cardiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors: L
authors: L
authors: Almenar-Bonet
authors: Department of Phsyiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors: E
authors: E
authors: Marqués-Sulé
authors: Department of Cardiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors: J
authors: J
authors: Melero-Ferrer
authors: Research Center, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors: M
authors: M
authors: Portolés-Sanz
authors: Research Center, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors: M
authors: M
authors: Rivera-Otero
authors: Department of Cardiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors: D
authors: D
authors: Domingo-Valero
authors: Department of Cardiovascular Surgery, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors: A
authors: A
authors: Montero-Argudo
mesh_terms: D000328:Adult; D015992:Body Mass Index; D065095:Calcineurin Inhibitors / Q000009:adverse effects*; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009765:Obesity / Q000139:chemically induced* / Q000453:epidemiology; D016017:Odds Ratio; D016559:Tacrolimus / Q000009:adverse effects*; D015430:Weight Gain
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus